HOLX * Stock Overview Engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hologic, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hologic Historical stock prices Current Share Price US$1,207.71 52 Week High US$1,265.13 52 Week Low US$1,207.71 Beta 1.02 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -21.17% 5 Year Change 31.85% Change since IPO 36.31%
Recent News & Updates Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence
Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection Nov 26
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025 Nov 05
Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024 Oct 04
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares. Sep 14 See more updates Hologic, Inc. Announces New Data to Be Presented At SABCS 2024 Investigates the Potential Role of the Breast Cancer Index Test in Identifying Patients with Minimal Risk of Distant Recurrence
Hologic, Inc. to Showcase AI-Powered Breast Imaging Advancements Designed to Assess Breast Density, Enhance Workflows and Improve Cancer Detection Nov 26
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025 Nov 05
Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024 Oct 04
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares. Sep 14 Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million. Jul 25
Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024 Jul 04 Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024
Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million. Apr 30
Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024 Apr 03
Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test Mar 06 Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024
Hologic, Inc., Annual General Meeting, Mar 07, 2024 Jan 19
Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc Jan 13
Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024 Jan 08
Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024 Jan 05
Independent Director recently sold Mex$12m worth of stock Dec 16
Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer Dec 08
Insider recently sold Mex$9.3m worth of stock Nov 25
Full year 2023 earnings released: EPS: US$1.85 (vs US$5.18 in FY 2022) Nov 24
Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024 Nov 12
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares. Nov 10
Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023 Oct 06
Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors Sep 23
New minor risk - Earnings quality Aug 30
Insufficient new directors Aug 30
Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023 Aug 03 Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023
Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023 Jul 06
Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay May 20
Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe Feb 16
First quarter 2023 earnings released: EPS: US$0.76 (vs US$1.97 in 1Q 2022) Feb 04
Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023 Feb 03
Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023 Feb 02
Hologic, Inc., Annual General Meeting, Mar 09, 2023 Jan 20
Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023 Jan 09
Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023 Jan 04
Insider recently sold Mex$2.5m worth of stock Dec 18
Hologic, Inc. Appoints Stacey D. Stewart to the Board of Directors, Effective January 2, 2023 Dec 10
Hologic, Inc. and Biotheranostics, Inc. Announce New Data Present At SABCS 2022 Dec 07
Chairman recently sold Mex$49m worth of stock Dec 03
Insufficient new directors Nov 16
Full year 2022 earnings released: EPS: US$5.18 (vs US$7.28 in FY 2021) Nov 01 Hologic, Inc. Provides Earnings Guidance for the First Quarter Ending December 31, 2022 and Year Ending September 30, 2023
Insufficient new directors Oct 05
Hologic, Inc. to Report Q4, 2022 Results on Oct 31, 2022 Oct 05
Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,000 million worth of its shares. Sep 24
Insufficient new directors Sep 02
Hologic, Inc. Announces Separation of Sean S. Daugherty as President, Effective September 30, 2022 Aug 31
U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case Aug 12 Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 24, 2022
Hologic, Inc. Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV Jul 12
Hologic, Inc. to Report Q3, 2022 Results on Jul 27, 2022 Jul 06
Insufficient new directors May 31
Hologic Announces FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus May 12
Hologic, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Apr 28
Hologic, Inc. to Report Q2, 2022 Results on Apr 27, 2022 Apr 05
Insufficient new directors Feb 15 Hologic, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2022
Hologic, Inc. Provides Preliminary Revenue Guidance for First Fiscal Quarter Ended December 25, 2021 Jan 10
Hologic Adds Aptima SARS-CoV-2 Assay to Its Global Access Initiative in Resource-Limited Countries Jan 06
Hologic, Inc. Launches Panther Trax for High Volume Molecular Testing Dec 24
Hologic, Inc. and Biotheranostics, Inc. Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation Dec 11 Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Bolder Surgical, LLC from Providence Ventures, LLC.
Insider recently sold Mex$4.1m worth of stock Nov 25
Hologic, Inc. to Showcase its Extensive Portfolio of Breast and Skeletal Health Products At RSNA 2021 Nov 24
Full year 2021 earnings released: EPS US$7.28 (vs US$4.25 in FY 2020) Nov 19
Third quarter 2021 earnings released: EPS US$1.05 (vs US$0.53 in 3Q 2020) Aug 02
Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test Jul 15
Hologic, Inc.(NasdaqGS:HOLX) dropped from Russell 1000 Growth Index Jun 28
Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Mobidiag Oy from Autobio Diagnostics Co., Ltd. (SHSE:603658) and others for an enterprise value of approximately $810 million Jun 18
Hologic, Inc. Announces American College of Obstetricians and Gynecologists' Updated Guidance Supports Use of Laparoscopic Radiofrequency Ablation for the Treatment of Uterine Fibroids May 25
Insider recently sold Mex$5.2m worth of stock May 13
Second quarter 2021 earnings released: EPS US$2.40 (vs US$0.37 in 2Q 2020) Apr 29
Hologic, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal Year 2021 Apr 29
Hologic, Inc. (NasdaqGS:HOLX) acquired Diagenode s.a. for approximately $160 million. Mar 03
Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of BioTheranostics, Inc. Feb 24
Insider recently sold Mex$10m worth of stock Feb 10
Hologic, Inc. Announces Multiyear Strategic Collaboration with Google Cloud Feb 02 Shareholder Returns HOLX * MX Medical Equipment MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Market: Insufficient data to determine how HOLX * performed against the MX Market .
Price Volatility Is HOLX *'s price volatile compared to industry and market? HOLX * volatility HOLX * Average Weekly Movement n/a Medical Equipment Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: HOLX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HOLX *'s volatility change over the past year.
About the Company Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Show more Hologic, Inc. Fundamentals Summary How do Hologic's earnings and revenue compare to its market cap? HOLX * fundamental statistics Market cap Mex$294.22b Earnings (TTM ) Mex$8.77b Revenue (TTM ) Mex$67.55b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) HOLX * income statement (TTM ) Revenue US$3.97b Cost of Revenue US$1.55b Gross Profit US$2.42b Other Expenses US$1.91b Earnings US$515.10m
Last Reported Earnings
Dec 30, 2023
Earnings per share (EPS) 2.19 Gross Margin 60.99% Net Profit Margin 12.98% Debt/Equity Ratio 55.0%
How did HOLX * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/03/03 09:59 End of Day Share Price 2023/12/05 00:00 Earnings 2023/12/30 Annual Earnings 2023/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hologic, Inc. is covered by 51 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Ishan Majumdar Baptista Research Charles Butler Barclays
Show 48 more analysts 
